A Comparison of SGLT2 or DPP-4 Inhibitor Monotherapy vs Placebo for Type 2 Diabetes in Adolescents vs Young Adults.

J Endocr Soc · 2025 · PMC12206083 · PMID 40585887

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

In addition, there was a numerical trend for a reduction in HbA1c in the treatment arms of both the adolescent and young adult study samples vs placebo, with empagliflozin treatment.

also in 536 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.